ClinicalTrials.gg
CompletedNCT06738277Updated Aug 19, 2025

This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).

A Phase 1 interventional study of Bmab 1200 (Biosimilar Ustekinumab) in Moderate to Severe Chronic Plaque Psoriasis, sponsored by Biocon Biologics UK Ltd. Completed at 1 site in India. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Biocon Biologics UK Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Psoriasis with a site in India — 1 open to participants now, 2 under way, 1 of them phase 3. Psoriasis · India.

Enrollment
6th of 19
186 · median 90
Started
2025
the only one that year
Phase 1
2 of 19
none open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Biocon Biologics UK Ltd

Among the 19 studies in Psoriasis with a site in India, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 2 in phase 1, and was the 18th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 19 studies in Psoriasis with a site in India is open now. Recruiting first, the newest first:

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Psoriasis with a site in India, or all of them as a file.
02

Study summary

This is an open-label, 2-arm parallel-group study in normal healthy subjects to evaluate pharmacokinetics, safety, tolerability of Bmab 1200 -autoinjector (AI) after single subcutaneous injection (45 mg) in comparison with Bmab 1200 -prefilled syringe (PFS).

Read the detailed description

Bmab 1200 is being developed as a proposed biosimilar product to the reference product Stelara® in accordance with EU and US biosimilar guidelines. The currently available Bmab 1200 formulation is administered via SC injection using PFS (similar to the reference product Stelara®). The main purpose of this study is to establish the PK equivalence of Bmab 1200 -AI following a single SC injection ( 45 mg) in comparison with Bmab 1200 -PFS. AI and PFS are self-injectable devices that can deliver drugs through the SC route. This study will also assess the safety and tolerability of Bmab 1200 AI in comparison with Bmab 1200 PFS. This will enable the licensure of AI to improve patient compliance through controlled and standardized administration of Bmab 1200

03

Conditions studied

  • Moderate to Severe Chronic Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a.Non-smokers, healthy, adult, human volunteers between 18 to 55 years of age (both inclusive).

    b.Having between 18.5 to 28.0 m2 and having a body weight between 60 kg and 90 kg (both inclusive for both parameters).

    c.Not having any significant diseases or abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead and X-ray chest (P/A view) recordings.

    d.Able to understand and comply with the study procedures, in the opinion of the investigator.

    e.Able to give voluntary written for participation in the study.

    f.Subjects should not receive a BCG vaccine within 1 year before dosing and agree to not take it during the study and at least 1 year after dosing.

    g.Subjects will agree not to receive during the study. h.Subject will agree not to donate blood/ plasma/ during the study and at least 3 months after the end of study.

    i.For male subjects i.Subjects agree to use effective (e.g. Double barrier method) and refrain from donation of sperm from check-in until 90 days after the end of study.

    j.In case of female subjects: i.Surgically sterilized at least 6 months prior to study participation Or If subject is of , is willing to use a suitable and effective double barrier contraceptive method or intrauterine device during the study and till 4 months after the end of study.

Or women. And ii.Serum pregnancy test must be negative. iii.Subjects will agree to refrain from donation of ova from check-in until 90 days after the end of study.

Exclusion criteria

Exclusion Criteria:

  • a. Known or idiosyncratic reaction to ustekinumab or any or any related drug or any substance (specifically any biologic product or the constituents of Bmab 1200).

    b. Known hypersensitivity to host cell [ murine myeloma cell or Chinese hamster ovary cells] derived proteins, latex), food, or other substance.

    c. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal, or any other body system.

    d. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes.

    e. Use or intend to use any prescription medications/products or other acceptable concomitant Medications within 30 days prior to dosing or slow-release medications/products considered to still be active within 14 days prior to check-in.

    f. Use or intend to use any nonprescription medications/ products, including vitamins, minerals, and phytotherapeutic/ herbal/ plant-derived preparations within 7 days prior to check-in.

    g. Use of any vaccine from 4 weeks prior to screening.

    h. The more than 450 ms for male and more than 460 ms for female at the time of screening.

    i. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or NSAIDs induced urticaria.

    j. A recent history of harmful use of alcohol (less than 2 years), or consumption of alcohol or alcoholic products within 48 hours prior to receiving study drug.

    k. Smokers, or who have smoked within the last six months prior to the start of the study.

    l. The presence of abnormal laboratory values during screening.

    m. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.

    n. History or presence of seizure or psychiatric disorders.

    o. A history of difficulty with donating blood.

    p. Donation of blood (1 unit or 350 mL) or plasma/ in the last 90 days prior to screening until 3 months after the end of study visit.

    q. Participation in a clinical study involving the administration of an drug in the past 90 days or 5 half-lives (whichever is longer), prior to dosing.

    r. A positive hepatitis screen including surface antigen and/or antibodies.

    s. A positive test result for antibody (I \&/or 2).

    t. Current history of active infections, including significant localized infections, cough or fever, or current /previous history of recurrent or chronic infections. (At screening and within 1 week prior to study drug administration).

    u. History of active tuberculosis (TB) or presence of active or latent TB. A positive result for IGRA (Interferon Gamma Release Assay) test at screening.

    v. Known history of previous exposure to ustekinumab or ustekinumab biosimilar, or any IL-12 or IL-23 monoclonal antibodies, approved or investigational.

    w. Consumption of grapefruit or grapefruit products within 72 hours prior to dosing.

    x. An unusual diet, for whatever reason (for example, fasting, high potassium or low sodium), for four weeks prior to receiving the study medicine. In any such case, subject selection will be at the discretion of the Principal Investigator.

    y. Ingestion of poppy seed-containing foods or beverages within 7 days prior to check-in.

    z. Receipt of blood products within 2 months prior to check-in. aa. Poor peripheral venous access.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Bmab 1200 AI (Biosimilar Ustekinumab)

    Drug: Bmab 1200 (Biosimilar Ustekinumab)

  • Active comparator
    Bmab 1200 PFS (Biosimilar Ustekinumab)

    Drug: Bmab 1200 (Biosimilar Ustekinumab)

Interventions

  • DrugBmab 1200 (Biosimilar Ustekinumab)

    Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed concentration (Cmax) of drug Bmab 1200

    Time frame: Week 16

  2. AUCo-∞

    Comparison of area under the concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: Week 16

Secondary outcomes

  1. AUCo-t

    Area Under the serum Concentration versus time curve from time 0 to the last sampling time at which concentrations were at or above the limit of quantification

    Time frame: Week 16

  2. Tmax

    Time to maximum observed concentration

    Time frame: Week 16

  3. AUC_%Extrap_obs

    % of the AUC that has been derived after extrapolation

    Time frame: Week 16

  4. ƛz

    Elimination rate constant

    Time frame: Week 16

  5. Vd

    Volume of distribution

    Time frame: Week 16

  6. Cl

    drug clearance

    Time frame: Week 16

  7. t1/2

    Apparent terminal elimination half-life

    Time frame: Week 16

07

Study locations

1 site
  • Lambda Therapeutic Research Ltd
    Ahmedabad, 382481, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jul 2025, 6 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 17, 2024
StartActual
Jan 9, 2025
Primary completionActual
Jul 12, 2025
CompletionActual
Jul 12, 2025
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06738277
Lead sponsor
Biocon Biologics UK Ltd
Responsible party
Sponsor
First posted
Dec 17, 2024
Start date
Jan 9, 2025
Primary completion
Jul 12, 2025
Completion
Jul 12, 2025
Last update
Aug 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion